1Bonadonna G, Brusamolion E, Valagussa P, et al.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 1976, 294: 405--410.
2Bonadonna G, Moliterni A, Zambetti M, etal. 30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 2005, 330: 217--220.
3Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: n overview of the randomized trials. Lancet, 1998, 352 : 930-- 932.
4Early breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998,351: 1451-- 1467.
5Henderson IC, Berry D, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not ,from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003, 21:976--983.
6Mamounas EP, Bryant J, Lembersky BC, et al. paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B28. Proc Am Soc Clin Oncol, 2003, 22:12.
7Martin M, Pienkowski T, Mackey J, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat, 2003, 82:43.
8Citron M L,Berry D A,Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer; first report of intergroup trail C9741/ Cancer and leukemia Group B trial 9741. J Clin Oncol, 2003, 21:1431-1439.
9Sparano J A, Wang M, Martino S, et al. Phase III study of doxorubicin-cydophosphamide followd by paelitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. Proc Am Soc Clin Oncoh 2007, 25: 6s.
10Burnell IV M J,Levine M N,Chapman J A,etal. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NClC CTG MA. 21). Proc Am Soe Clin Oncol, 2007, 25: 15s.
